Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2015

View Archived Issues

Met inhibition shows promising preclinical results for the treatment of nasopharyngeal carcinoma

ONCOS-102 receives FDA orphan drug status for malignant mesothelioma

Palatin initiates phase III program for bremelanotide in female sexual dysfunction

FDA grants orphan drug and rare pediatric disease designations to entrectinib for neuroblastoma

AMAG and Takeda terminate ex-U.S. ferumoxytol agreement

Repros initiates phase IIb studies of Proellex for uterine fibroids

Lilly begins phase I study of LY-3202626 in healthy subjects and Alzheimer's patients

Nippon Zoki and AnGes cancel licensing agreement

Neuren provides update on the development of NNZ-2566

Idera Pharmaceuticals provides update on IMO-8400 in Waldenstrom's macroglobulinemia

NeuroDerm reports topline results from phase IIa study of ND-0612H and ND-0612L

OncoGenex to regain rights to custirsen from Teva Pharmaceutical

Aquinox initiates phase II study of AQX-1125 for atopic dermatitis

Vaccines for Gram-negative infections described in EIT+ patent

Shanghai Institute Materia Medica patents novel RTK inhibitors

MAGL inhibitor evaluated in a mouse model of ALS

Anti-CD47 MAb demonstrate efficacy in animal models of leukemia/lymphoma

Preclinical data presented on BBI-11008 for the treatment of L-DOPA-induced dyskinesia

Investigators in Barcelona prepare and test tyrosine-protein kinase inhibitors

Asceneuron synthesizes M1 receptor PAMs

Cathepsin D inhibitors in early development at Merck KGaA

Ampla Pharmaceuticals describes GPBAR1 agonists

Roche reports cannabinoid CB2 receptor agonists

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...